688137 近岸蛋白
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-1.380-2.5370.5857.08864.383
总资产报酬率 ROA (%)-1.308-2.4090.5556.37443.503
投入资产回报率 ROIC (%)-1.340-2.4530.5656.60951.428

边际利润分析
销售毛利率 (%)64.84062.37775.66886.32287.694
营业利润率 (%)-34.093-41.6134.25139.64951.761
息税前利润/营业总收入 (%)-54.098-69.126-13.88237.41051.922
净利润/营业总收入 (%)-25.801-42.6618.38434.29343.582

收益指标分析
经营活动净收益/利润总额(%)50.18471.822159.623102.128108.514
价值变动净收益/利润总额(%)-0.695-5.100276.2973.9160.483
营业外收支净额/利润总额(%)0.9542.099-4.6571.215-0.419

偿债能力分析
流动比率 (X)25.67329.12541.30433.3514.628
速动比率 (X)24.75427.99239.60832.1474.110
资产负债率 (%)5.2295.2504.8035.70929.883
带息债务/全部投入资本 (%)0.6511.0080.6360.6324.398
股东权益/带息债务 (%)14,978.8609,592.98415,201.72915,250.5371,772.249
股东权益/负债合计 (%)1,812.5351,804.8931,981.8661,651.570234.639
利息保障倍数 (X)2.7492.5970.774-13.720137.721

营运能力分析
应收账款周转天数 (天)158.396179.090218.365146.60362.972
存货周转天数 (天)496.213604.070782.545568.439239.151